Business
PRTC Presents Immuno-Oncology Programmes at AACR
PRTC Presents Immuno-Oncology Programmes at AACR.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \nRNS Number : 7625U PureTech Health PLC 02 April 2019 \n\n2 April 2019\n \nPureTech Health plc\n \nPureTech Health Announces Presentation of Internal Immuno-Oncology Programmes at American Association for Cancer Research (AACR) Annual Meeting \n \nFully-human mAb candidates represent potential first-in-class therapies with IND filing expected in 2020\n \nInternal development programmes targeting Galectin-9 (LYT-200) and γδ1 T cells (LYT-210) represent novel approaches to targeting immunosuppression in cancer\n \nPureTech Health plc (LSE: PRTC) (\"PureTech Health\"), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis, today announced the presentation of two scientific posters at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Georgia.\n \nJoseph Bolen, PhD, chief scientific officer at PureTech Health, said: \"PureTech Health has built a leading position in BIG therapeutic development through its affiliate technologies and is now capitalising on this critical mass of expertise through multiple internal development programmes that are delivering clinical candidates. We're proud to present data on these programmes at AACR, one of the premiere scientific meetings focused on cancer research. Galectin-9 and γδ1 T cells represent powerful immunosuppressive mechanisms across both innate and adaptive immunity. We have moved quickly to advance development of compelling candidates that could act as both monotherapies and combination therapies against cancers that currently do not respond well to approved immunotherapies. In addition to our programmes targeting the body's immune cell trafficking highway - the lymphatic system - these immuno-oncology programmes round out an exciting pipeline of therapeutics targeting important regulators of the immune system.\"\n \nThe posters detail the Company's development of first-in-class, fully-human monoclonal antibodies (mAbs) targeting Galectin-9 (LYT-200) and immunosuppressive γδ1 (gamma delta) T cells (LYT-210). LYT-200 and LYT-210 are unique mAbs targeting foundational, novel mechanisms of tumoral immune escape and immunosuppression in cancer, and have been tested as single agents, as well as in combination with anti-PD1 in preclinical murine and h...